Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Nivolumab in MMR-Proficient Colorectal Cancer
NCT03879811Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in colorectal cancer (CRC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Response Rate up to 2 years. Planned start Mar 2019; status: withdrawn.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03879811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879811.